The Impact of Qualia Vitamin C+ on Blood Vitamin C Levels

This is a randomized, double-blind, placebo-controlled, parallel-group, study evaluating the effect of a Qualia Vitamin C+ formulation on Whole Blood Vitamin C levels in the blood of healthy adults aged 25 years or older. Approximately 36 participants will be randomized to one of two study arms: Qualia Vitamin C+ or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in blood vitamin C levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related cognitive functioning and stress (PROMIS Cognitive Function - Short Form 8a and the Perceived Stress Scale-10), the Single-item Assessment of Immune Fitness, evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Study Overview

• Status: Completed
• Conditions: Vitamin C Deficiency
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: Qualia Vitamin C+

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Carlsbad, California, United States, 92011
      • Qualia Life Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion criteria:

Provide voluntary, written, informed consent to participate in the study. Agree to provide a valid cell phone number and are willing to receive communications through text.

Can read and write English. Willing to complete questionnaires, records, and diaries associated with the study.

Healthy male and female participants aged 25 years or older. Willing to go to an Ulta Labs Patient Service Center location for a Blood Vitamin C Test (baseline and Day 29) and located within a convenient distance of participating locations. [Note: The services offered by Ulta Lab Tests are available only in the United States and not to residents of the states of New Jersey, New York, and Rhode Island.] Willing to avoid starting new or stopping any existing dietary supplements throughout the study.

Exclusion criteria:

Women who are pregnant, breastfeeding, or planning to become pregnant or start breastfeeding during the trial.

Known food intolerances/allergy to any ingredients in the product. Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer.

Having had a significant cardiovascular event in the past 6 months. Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy. Adults lacking capacity to consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Rice flour placebo	Dietary supplement: Placebo; Rice flour
Active Comparator: Qualia Vitamin c+; Qualia Vitamin C+ manufactured by Qualia Life Sciences	Dietary supplement: Qualia Vitamin C+; Qualia Vitamin C+ manufactured by Qualia Life Sciences

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To Assess Between-group Differences in the Change in Blood Vitamin C Levels From Baseline to Day 28	To assess between-group differences in the change in blood Vitamin C levels from baseline to Day 28 following supplementation with Qualia Vitamin C+ versus placebo.	0-28 days

Secondary Outcome Measures

Outcome Measure	Time Frame
To assess within-group and between-group differences in PROMIS Cognitive Function - Short Form 8a	baseline to day 14 and 28
To assess within-group and between-group differences in Perceived Stress Scale-10 domain scores	baseline to day 14 and 28
To assess within-group and between-group differences in Single-item Assessment of Immune Fitness	baseline to day 14 and 28
To assess within-group differences in the change in blood Vitamin C levels	baseline to day 28
To evaluate side effect profiles using a custom Safety and Tolerability survey	baseline to day 14 and 28

Collaborators and Investigators

• Sponsor: Qualia Life Sciences

Study record dates

Study Major Dates

• Study Start (Actual): December 23, 2025
• Primary Completion (Actual): January 19, 2026
• Study Completion (Actual): March 11, 2026

Study Registration Dates

• First Submitted: December 3, 2025
• First Submitted That Met QC Criteria: December 3, 2025
• First Posted (Actual): December 16, 2025

Study Record Updates

• Last Update Posted (Actual): May 7, 2026
• Last Update Submitted That Met QC Criteria: May 5, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Avitaminosis; Deficiency Diseases; Malnutrition; Nutritional and Metabolic Diseases; Ascorbic Acid Deficiency
• Other Study ID Numbers: QLS-020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No